NEW YORK – Bio-Rad Laboratories said after the close of the market on Thursday that its fourth quarter revenues rose approximately 27 percent year over year.
Bio-Rad also announced it received Emergency Use Authorization from the US Food and Drug Administration for a combined COVID-19, influenza A, and influenza B multiplex syndromic RT-PCR test.